Phase II trial of sequential methotrexate and 5-fluorouracil with leucovorin in children with sarcomas.
Balis
F M
FM
Pediatric Branch, National Cancer Institute, Bethesda, MD.
Gillespie
A
A
Belasco
J
J
Reaman
G H
GH
Ettinger
L J
LJ
Murphy
R F
RF
Doherty
K
K
Jeffries
S
S
Horowitz
M E
ME
Poplack
D G
DG
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002851:Chromatography, High Pressure Liquid; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D004357:Drug Synergism; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D006801:Humans; D007262:Infusions, Intravenous; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D012208:Rhabdomyosarcoma / Q000188:drug therapy*; D012512:Sarcoma, Ewing / Q000188:drug therapy*
D002955:Leucovorin; D005472:Fluorouracil; D008727:Methotrexate